Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Debt-to-Equity : 0.23 (As of Mar. 2024)

Hangzhou Bio-Sincerity Pharma-Tech Co Debt-to-Equity Chart

Hangzhou Bio-Sincerity Pharma-Tech Co Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.10	0.11	0.11	0.14	0.23

Competitive Comparison of Hangzhou Bio-Sincerity Pharma-Tech Co's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Hangzhou Bio-Sincerity Pharma-Tech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Bio-Sincerity Pharma-Tech Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hangzhou Bio-Sincerity Pharma-Tech Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hangzhou Bio-Sincerity Pharma-Tech Co's Debt-to-Equity falls into.

Hangzhou Bio-Sincerity Pharma-Tech Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hangzhou Bio-Sincerity Pharma-Tech Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Hangzhou Bio-Sincerity Pharma-Tech Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Bio-Sincerity Pharma-Tech Co  (SZSE:301096) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hangzhou Bio-Sincerity Pharma-Tech Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hangzhou Bio-Sincerity Pharma-Tech Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Business Description